Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis
Mol Ther
.
2017 Oct 4;25(10):2235-2237.
doi: 10.1016/j.ymthe.2017.09.002.
Epub 2017 Sep 8.
Author
Steven A Greenberg
1
Affiliation
1
Brigham and Women's Hospital, Department of Neurology, Harvard Medical School, 60 Fenwood Road, Boston, MA 02115, USA. Electronic address: sagreenberg@bwh.harvard.edu.
PMID:
28927986
PMCID:
PMC5628928
DOI:
10.1016/j.ymthe.2017.09.002
No abstract available
Publication types
Letter
Comment
MeSH terms
Follistatin / genetics*
Genetic Therapy
Humans
Immunosuppressive Agents
Myositis, Inclusion Body*
Substances
Follistatin
Immunosuppressive Agents